What 8 Analyst Ratings Have To Say About Globus Medical
Globus Medical Price Target Raised to $78.00/Share From $60.00 by Wells Fargo
Wells Fargo Upgrades Globus Medical to Overweight From Equalweight, Adjusts Price Target to $78 From $60
Needham Reaffirms Their Hold Rating on Globus Medical (GMED)
Buy Rating Justified for Globus Medical on Strong Performance and Strategic Positioning
Globus Medical Analyst Ratings
Truist Raises Price Target on Globus Medical to $78 From $63, Maintains Hold Rating
Globus Medical Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Globus Medical, Raises Price Target to $71
Morgan Stanley Raises Price Target on Globus Medical to $71 From $67, Keeps Equalweight Rating
RBC Raises Price Target on Globus Medical to $76 From $70, Maintains Outperform Rating
Globus Medical Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Globus Medical (GMED), Irhythm Technologies (IRTC)
Globus Medical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Abivax SA Sponsored ADR (ABVX)
Morgan Stanley Raises Price Target on Globus Medical to $67 From $57, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)
Truist Financial Keeps Their Hold Rating on Globus Medical (GMED)
Globus Medical Analyst Ratings
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)